Heart Failure
Conditions
Keywords
chocolate,, heart failure,, endothelial function,, platelet adhesion,, oxidative stress,, baroreceptor function,
Brief summary
The aim of the present study is to investigate whether in patients with chronic heart failure endothelial dysfunction and baroreceptor function is altered by ingestion of a flavonoid-rich dark chocolate in comparison to placebo chocolate (Nestlé Placebo Chocolate) on top of standard medication. Moreover, we will evaluate the effect of chocolate on oxidative stress, platelet adhesion as well as systemic inflammatory response such as C-reactive protein and pro-inflammatory cytokines in patients with chronic heart failure.
Interventions
DIETARY_SUPPLEMENTNestlé Noir intense 40 grx2
daily intake of 40gr chocolate (Nestlé Noir intense or Nestlé Placebo Chocolate) in the morning and 40gr chocolate in the evening.
DIETARY_SUPPLEMENTNestlé Placebo Chocolate 40 grx2
Nestlé Placebo Chocolate 40 gr in the morning and 40gr chocolate in the evening.
Sponsors
University of Zurich
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
30 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Heart failure ( NYHA ≥II, LVEF\<50%, independent of aetiology) 2. Nonsmokers 3. Age: 30-80 4. Written obtained informed consent
Exclusion criteria
1. Decompensated Heart failure 2. Instable Angina pectoris 3. Smokers 4. Ventricular tachyarrhythmias or AV-Block \>I° 5. Renal failure (\>200 umol) 6. Liver disease (ALT or AST \>150 IU) 7. Diabetes mellitus 8. Obesity (BMI \>30 kg/m2) 9. Symptomatic hypotension, hypertension \>160/100mmHg 10. Known allergy to compounds of Nestlé noir intense 11. History of gastric ulcer or bleeding, current diarrhea 12. Venous thrombosis or pulmonary embolism, at present or recurrent history of Infectious disease, acutely or chronic 13. Disease with systemic inflammation (e.g. rheumatoid arthritis, M. Crohn) 14. Neoplasia (unless healed or remission \>5 years) 15. Participation in another study within the last month 16. Concomitant vitamin supplements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| endothelial function | acute (2 hours), chronic (2 and 4 weeks) |
Secondary
| Measure | Time frame |
|---|---|
| shear-stress dependent platelet function; Oxidative stress; baroreceptor function Systemic inflammatory response (assessed as change in high sensitivity CRP, 8-Isoprostanes, CD-40 ligand); Plasma epicatechins. | acute (2 hours), chronic (2 and 4 weeks) |
Countries
Switzerland
Outcome results
None listed